Patria Investments Limited (PAX)

RED BANK, N.J. , Sept. 23, 2025 /PRNewswire/ -- PAX Health, a leading behavioral healthcare company backed by HCAP Partners and funds managed by Hamilton Lane (Nasdaq:HLNE), today announced its acquisition of Neuropsychology and Counseling Associates, a comprehensive outpatient mental health practice serving children, adolescents, adults, and families throughout New Jersey.

Patria Investments Limited - Special Call Company Participants Andre Medina Merrick McKay - Partner & Head of Private Equity for Global Private Markets Solutions Presentation Andre Medina Hello, everyone. I'm Andre Medina, leading Shareholder Relations at Patria, and welcome to the third edition of our PAX Talks, an investor-driven deep dive into our Global Private Market Solutions business or GPMS and how we generate Alpha in middle market private equity.

Patria Investments is gaining momentum in alternatives, growing fee-earning AUM 20% YoY and outpacing fundraising targets despite a cautious market. The stock trades at a discount to peers, offers a 4%+ dividend yield, and just authorized a buyback, making the income-growth mix appealing. Recent earnings misses are mainly timing-related, not structural; patient investors can look past short-term noise for long-term upside.

REITs are offering historically high dividend yields right now. They can be great investments to earn passive income. I highlight my three REITs, earning me $2,000 each month.

Patria Investments is delivering strong double-digit AUM and earnings growth, nearing 2027 targets, and shifting toward a more shareholder-focused model. The company built a scalable, resilient investment portfolio, robust balance sheet, and attractive dividend yield, with buybacks planned to stabilize share count. PAX is well-positioned to benefit from global capital shifts into Latin America, especially as US rate cuts make the region more attractive for investors.

Patria Investments Limited (NASDAQ:PAX ) Q2 2025 Earnings Conference Call August 1, 2025 9:00 AM ET Company Participants Alexandre Teixeira de Assumpcao Saigh - Co-Founder, CEO, Senior Managing Partner & Director Ana Cristina Russo - MD & CFO Rob Lee - Head of Shareholder Relations Conference Call Participants Daer Labarta - Goldman Sachs Group, Inc., Research Division Guilherme F. Grespan - JPMorgan Chase & Co, Research Division Ricardo Buchpiguel - Banco BTG Pactual S.A.

Patria Investments (PAX) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.22 per share a year ago.

GRAND CAYMAN, Cayman Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Patria (Nasdaq:PAX) reported today its unaudited results for the second quarter ended June 30, 2025. The full detailed presentation of Patria's second quarter 2025 results can be accessed on the Shareholders section of Patria's website at https://ir.patria.com/.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Patria Investments (PAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors looking for stocks in the Financial - Investment Management sector might want to consider either Patria Investments (PAX) or Apollo Global Management Inc. (APO). But which of these two stocks presents investors with the better value opportunity right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

GRAND CAYMAN, Cayman Islands, July 08, 2025 (GLOBE NEWSWIRE) -- Patria (Nasdaq:PAX) announced today that it will release financial results for the second quarter 2025 on Friday, August 1, 2025, and host a conference call via public webcast at 9:00 a.m. ET.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK government's National Institute for Health and.

Patria Investments is finally getting some love. But even after its recent surge, it remains deeply undervalued. I expect a lot more upside. Here is why.

Investors looking for quality businesses with strong balance sheets typically have to choose between growth and yield. However, on rare occasions, Mr. Market offers quality opportunities that provide both yield and growth. We share 2 of some of our top picks of the moment that combine these traits and appear set to soar.